Peptide Half-Life Comparison: Stability by Compound Class

The number most people quote for a peptide's half-life describes one thing only: how fast the molecule disappears from blood plasma. It says nothing about whether the vial in the freezer is still intact. Those are two separate clocks running on two separate sets of chemistry, and collapsing them into one figure is the single most common error in the peptide half-life comparison charts circulating online.

We synthesise research peptides in small batches and read the certificate on every one. The key question is this: is this compound losing signal because of its molecular design, or because of how it was shipped, mixed, and stored? Those have completely different fixes.

What does a peptide half-life comparison actually measure?

A peptide half-life comparison measures how long a compound stays in circulation before enzymatic cleavage and renal filtration remove half of it. Reported values span roughly 1.5 minutes for native GLP-1 to about one week for semaglutide. Circulating half-life is fixed by molecular structure, not by how carefully the vial is stored.

The oversimplification worth killing early: a longer half-life does not mean a better or more stable compound. It means the molecule was engineered to resist specific proteases or to bind albumin, and that engineering carries trade-offs in control and pulsatility. What follows covers the clearance pathways that set circulation time, the structural modifications that extend it, a full peptide half-life comparison table across compound classes, and what those numbers do and do not imply for benchtop handling.

Two clocks run on every peptide, and they are not the same

Circulating half-life and shelf stability are independent properties. A compound can clear from plasma in ninety seconds and still sit perfectly stable as a lyophilised powder at minus 20 degrees Celsius for years. Native GLP-1 (7-36 amide) is the textbook case: a reported plasma half-life of roughly 1.5 to 2 minutes, with dry powder that holds its purity for extended periods under correct storage.

Circulating half-life is decided by sequence and structure. Proteases recognise specific cleavage sites, the kidney filters anything small enough to pass the glomerulus, and albumin binding determines whether a molecule can hide from both. None of that chemistry applies inside a sealed vial. Benchtop stability is governed by temperature, moisture, pH, oxygen exposure, light, and the number of freeze-thaw cycles the material has been through.

This is why a peptide half-life comparison built only from pharmacokinetic values misleads anyone actually handling material. The figure tells a researcher how to space sampling intervals in an animal model. It tells them nothing about whether the reconstituted solution in the fridge still matches the purity printed on its certificate of analysis.

The questions that arrive after a failed experiment are almost never about pharmacokinetics. They are about cold chain: what temperature the parcel hit in transit, how many thaw cycles the aliquot saw, whether the diluent was appropriate for that sequence. The molecule was usually fine when it shipped.

The enzymes and filters that set circulating half-life

Four clearance mechanisms account for most of the variation in any peptide half-life comparison: DPP-4 cleavage, neprilysin activity, general aminopeptidase digestion, and renal filtration.

DPP-4 (dipeptidyl peptidase-4) is a serine protease that clips two residues from the N-terminus whenever position two is alanine or proline. That single structural vulnerability is why native GLP-1 survives roughly two minutes in plasma. NEP 24.11 (neprilysin), a zinc metallopeptidase abundant in kidney and vascular tissue, cuts at hydrophobic residues mid-chain. Ubiquitous aminopeptidases chew inward from any unprotected terminus. Renal glomerular filtration then removes essentially anything below about 5 kDa that is not bound to a carrier protein, which covers the large majority of research peptides.

Here is the part most stability guides skip entirely. The degradation that ruins a vial on the bench is chemical, not enzymatic, and it is invisible. Methionine and cysteine residues oxidise. Asparagine and glutamine deamidate. Aspartate isomerises. Unprotected N-terminal residues can cyclise into diketopiperazines. Every one of those reactions proceeds inside a sterile, sealed, correctly refrigerated vial, and not one of them changes how the solution looks. Clear liquid is not evidence of intact peptide.

That is the practical argument for reading a dated certificate of analysis rather than trusting appearance, and it is why we publish batch documentation for every compound we synthesise instead of asking researchers to take purity on faith.

Modifications that extend half-life, and the trade-offs they carry

Four structural strategies dominate the long-acting end of any peptide half-life comparison. Each one buys circulation time by making the molecule harder for proteases or kidneys to process.

Acylation attaches a fatty acid chain that binds reversibly to serum albumin, turning a small filtered peptide into part of a large protein complex. Liraglutide uses a C16 palmitoyl chain and shows a reported half-life of roughly 13 hours. Semaglutide uses a C18 diacid with a spacer and reaches approximately one week. Similar backbone chemistry, radically different residence time.

Aib substitution replaces the DPP-4 vulnerable residue at position 8 with alpha-aminoisobutyric acid, a non-natural amino acid the protease cannot cleave. Semaglutide and tirzepatide both use it, and tirzepatide's reported half-life is approximately five days.

Covalent albumin binding, sold under the DAC label (drug affinity complex), uses a maleimide group that attaches to cysteine 34 on circulating albumin. Published clinical pharmacokinetic work on CJC-1295 with DAC reported a half-life measured in days, against roughly 30 minutes for the unmodified CJC-1295 No DAC fragment.

The cost of all this is control. Long-acting analogues hold receptor occupancy flat and erase the pulsatile signalling that short fragments preserve. For research modelling physiological rhythm, a short half-life is the feature, not the defect.

Peptide half-life comparison across compound classes

Reported values shift with species, route, assay method, and whether the study measured terminal or distribution phase, so treat every figure below as a published range rather than a fixed constant. Where no validated human pharmacokinetic data exists, this peptide half-life comparison says so rather than guessing, and all compounds listed are research chemicals rather than approved drug products.

What If: Stability and Storage Scenarios

What if a peptide shipment arrived at room temperature after several days in transit?

Check the compound class before assuming loss. Lyophilised powder is far more forgiving than most people expect, because the degradation reactions that matter need water to proceed, and a properly dried vial contains very little. Ambient excursions of a few days are a routine part of shipping research peptides and rarely produce measurable purity loss in dry material. A reconstituted vial that warmed above 8 degrees Celsius for the same period is a different situation entirely, and the only honest answer is to re-verify against the certificate rather than assume.

What if two suppliers list different half-life values for the same compound?

Assume both are quoting different studies and neither is quoting a wrong one. The red flag is a precise figure with no citation attached, particularly for compounds where no validated human pharmacokinetic study has ever been published.

What if a reconstituted vial looks completely clear but assay results have drifted?

Suspect chemical degradation, not contamination. Oxidation and deamidation change molecular mass and receptor binding without changing turbidity, colour, or odour, so visual inspection cannot detect them. Freeze-thaw cycling is the most common accelerant in a lab setting, because each cycle concentrates solutes at the ice boundary and stresses the peptide backbone. Aliquoting on the day of reconstitution, rather than repeatedly drawing from one vial, removes most of that variable.

What if a compound with a very short plasma half-life still shows activity hours later?

Separate pharmacokinetics from pharmacodynamics. A peptide can be fully cleared from plasma while the receptor cascade it triggered continues, which is exactly why short-acting GHRH fragments and regulatory peptides such as Selank produce effects that outlast measurable circulating concentration. Plasma half-life describes the messenger, not the message. Study designs that sample only for the duration of the half-life routinely miss the downstream signal.

The uncomfortable truth about published half-life numbers

Here's the honest answer: a large share of the half-life figures repeated across peptide forums and supplier pages have no traceable primary source. They get copied from one page to the next until repetition looks like consensus. For several popular research compounds, the correct entry in a peptide half-life comparison is not a number at all, it is the phrase 'not established in published human pharmacokinetics'. Writing that takes discipline, because a blank cell looks less authoritative than an invented one. If your interest in these compounds comes from an animal health question rather than a bench one, that conversation belongs with a licensed veterinarian.

Every batch we synthesise ships with third-party analytical documentation, and current results are published in our certificate of analysis library. Researchers comparing stability across delivery formats can review the oral research compounds collection alongside the full catalog, and cold chain and fulfilment details are listed on our locations page. Peptides frequently cited in stability work, including BPC-157, TB-500, and Ipamorelin, are supplied with matching batch documentation.

Spend enough time with a peptide half-life comparison and the hierarchy inverts. The compounds with the shortest circulating lives are often the most useful at the bench, because a signal that starts and stops cleanly is a signal you can actually attribute. Engineered persistence is a clinical convenience, not a research virtue. The real discipline is knowing which clock you are reading: the one inside the organism, which the molecule's structure decides for you, or the one inside the vial, which is entirely yours to protect.